◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 1244

3D Medicines Inc. (1244) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-11

3D Medicines Inc. (1244) operates in the Biotechnology industry and is headquartered in Qingdao, China with about 162 employees. Its market capitalization is roughly CNY 514 million. In the fiscal year ended 2025-12-31, 1244 reported CNY 356M in revenue and (CNY 178M) in net income.

3D Medicines Inc., a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products in the People's Republic of China.

Interactive charts & full statements →

1244 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 356MCNY 446MCNY 635MCNY 567M
Gross ProfitCNY 328MCNY 409MCNY 586MCNY 525M
Operating Income (EBIT)(CNY 74M)(CNY 79M)(CNY 421M)(CNY 321M)
Net Income(CNY 178M)(CNY 183M)(CNY 525M)(CNY 1.0B)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1244 Free Cash Flow History

1244 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 936MCNY 1.2BCNY 1.4BCNY 1.3B
Total LiabilitiesCNY 391MCNY 512MCNY 558MCNY 437M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1244 viewer.

Other Companies in Biotechnology

← 1243All “0-9” companies1245 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.